Type 1 diabetes affects increasingly large numbers of people globally (including at least half a million children under the age of 14 years) and it remains an illness with life-long and often devastating consequences. It is surprising, therefore, that the underlying aetiology of Type 1 diabetes remains poorly understood. This is largely because the cellular and molecular processes leading to the loss of b cells in the pancreas have rarely been studied at, or soon after, the onset of disease. Where such studies have been undertaken, a number of surprises have emerged which serve to challenge conventional wisdom. In particular, it is increasingly understood that the process of islet inflammation (insulitis) is much less florid in humans than in certain animal models. Moreover, the profile of immune cells involved in the inflammatory attack on b cells is variable and this variation occurs at the level of individual patients. As a result, two distinct profiles of insulitis have now been defined that are differentially aggressive and that might, therefore, require specifically tailored therapeutic approaches to slow the progression of disease. In addition, the outcomes are also different in that the more aggressive form (termed 'CD20Hi') is associated with extensive b-cell loss and an early age of disease onset (<7 years), while the less aggressive profile (known as 'CD20Lo') is associated with later onset (>13 years) and the retention of a higher proportion of residual b cells. In the present review, these new findings are explained and their implications evaluated in terms of future therapies.
Introduction
Type 1 diabetes is increasing in incidence in many Westernized countries [1, 2] , and the rate of increase is dramatic, reaching between 2% and 5% per annum in some populations [2, 3] . Thus, the absolute number of people living with Type 1 diabetes is rising and, in the UK alone, it is estimated that~340 000 people currently have the disease, including almost 40 000 children. Type 1 diabetes is an illness that is encountered frequently in both primary and secondary care settings, and is one for which effective therapeutic strategies have long been available. The objective of preventing or reversing the disease in humans, however, remains well beyond reach. This may seem disappointing given the length of collective experience among the scientific community and the frequency with which the disease presents in a clinical setting. Indeed, it might reasonably be imagined that a firm understanding of both the causes and the mechanisms that promote Type 1 diabetes would have been gained before now. In fact, nothing could be further from the truth. Thus, while persuasive evidence implicates cells of the immune system in mediating b-cell loss in people with Type 1 diabetes [2, 4, 5] , the cellular and molecular events that precipitate and perpetuate b-cell death remain largely mysterious. And there is good reason for this.
In order to probe the basis of b-cell death in humans effectively, access must be gained to the relevant organ (the pancreas) during the time that the process is happening. Herein lies the difficulty. The pancreas is an inaccessible target in living people and, although non-invasive methods are in development to image immune-mediated processes [6, 7] , these currently lack resolution. Moreover, a recent trial of a biopsy method designed to recover significant quantities of pancreatic tissue from living donors with Type 1 diabetes has been closed to recruitment in the face of unexpected surgical complications [8] . Hence, in most circumstances, the organ only becomes available for detailed histological analysis upon the death of the individual. Thankfully, for most people with Type 1 diabetes, this is delayed by many years after initial diagnosis but there is an obvious consequence for research. Namely, the number of individuals in whom the destructive process causing b-cell death has been examined histologically at (or very soon after) disease onset is extremely small. In fact, worldwide it is estimated that the pancreases of fewer than 200 such individuals have been made available for study since the beginning of the 20 th century [9] . Thus, the collective knowledge base of the scientific and clinical community working in this field derives from a remarkably modest sample. In other words, while Type 1 diabetes is an increasingly common illness that affects many millions of people across the world, the disease process has still been studied in situ in only a few select individuals.
In an attempt to remedy this, several far-sighted investigators have attempted to establish collections of pancreases for study, the first of which was an important biobank compiled by Professor Willy Gepts (Brussels) in the 1960s [10] . The largest such resource followed some 20 years later as a result of the sterling efforts of Professor Alan Foulis (Glasgow) [11] and, arguably, his biobank remains the single most important collection of recent-onset Type 1 diabetes pancreas samples, worldwide. More recently, the Juvenile Diabetes Research Foundation (JDRF)-funded network of Pancreatic Organ donors with Diabetes (nPOD) has been instrumental in driving forward efforts to supplement the existing biobanks by establishing a further tissue collection from across the USA [12] . Despite this, however, it remains true that the number of recent-onset Type 1 diabetes cases from whom pancreas samples are available for detailed histological analysis has risen only modestly during the past decade. My team has been extremely fortunate to have been given access to a large proportion of these and, in particular, through the generosity of Professor Foulis, we now curate his collection (Exeter Archival Diabetes Biobank). When coupled with advances in imaging technology, access to these samples has given us, and others, an unprecedented opportunity to examine the pancreas in detail at the onset of disease. This has revealed new insights about the process of disease which we anticipate will lead to improved therapeutic interventions in the future. In the present article, I aim to summarize the main, and the more surprising, findings.
Insulitis: a critical mechanism in Type 1 diabetes?
The relative lack of information deriving from human pancreas at the onset of Type 1 diabetes has led many investigators to explore the process in animal models. In particular, the non-obese diabetic (NOD) mouse [13, 14] and BioBreeding (BB) and LEW 1AR1/-iddm rats [15, 16] have proved popular, and each has yielded insights that have provided a critical backdrop against which the human disease can be assessed. Among these, is the concept that a defining feature of Type 1 diabetes is the presence of insulitis. Insulitis is a process of immune cell infiltration in which the islets of Langerhans become inflamed [9, 17] and, in most animal models (except, perhaps, certain breeds of dog [18] ), this inflammation is both intense and penetrative. In humans, it may be equally true that insulitis plays a critical role in disease [19, 20] , but analysis of pancreas specimens has revealed that its features are rather different. So much so that, when reviewing the human evidence critically, In't Veld was persuaded to label insulitis as an 'elusive lesion' in human pancreas [9] . This illustrates immediately that there are important variations between rodent models and the human disease, and it is abundantly clear from our studies that, in most people with Type 1 diabetes, the inflammatory infiltrates are much less florid than in rodents [20] [21] [22] . Nevertheless, insulitis is present in the majority of recentonset cases studied (including each of the six living donors from whom pancreas biopsies were recently collected [23] ), and it almost certainly contributes to b-cell loss.
As a means to gain an improved understanding of the role of insulitis in human Type 1 diabetes, both the disposition of the infiltrating immune cells and the composition of the infiltrates have been studied. This has revealed that the majority of influent cells are lymphocytic in nature, while only small numbers of monocytes and macrophages engage in the immune assault [17, 20, 21, 24] . Neutrophils and NK cells may also play a role in some circumstances [25, 26] ; however, one surprising feature is that the infiltrating cells
What's new?
• Pancreatic histopathology has been studied in fewer than 200 people with recent-onset Type 1 diabetes, worldwide.
• Human islets become inflamed during b-cell loss but, typically, the number of influent immune cells is modest. Immune cells are frequently arranged peripherally around the islets and few penetrate the islet core.
• Two phenotypic profiles of insulitis can be defined. Both are characterized by a preponderance of CD8+ T cells but the proportion of CD20+ B cells is more variable.
• The more aggressive form of insulitis (CD20Hi) comprises roughly equal proportions of CD8+ and CD20+ cells, while the less aggressive form (CD20Lo) has fewer CD20 cells.
• The two forms of insulitis are associated with different ages of disease onset and with differing proportions of residual insulin-containing islets at onset.
• An improved understanding of the significance of these profiles of insulitis is critical to the appropriate design of immunotherapeutic strategies aimed to slow disease progression.
are frequently arranged peripherally around the islets in humans and they penetrate into the islet core much less frequently ( Fig. 1 ). This contrasts with the situation in the NOD mouse where, on histological examination, inflamed islets often display both an extensive intra-islet infiltration as well as a large peripheral mantle of immune cells [27] .
The number and disposition of the cells in the islets in human pancreas raises several important issues. Firstly, it has a bearing on the route by which these cells reach the islets and suggests, for example, that they do not egress directly from intra-islet capillaries. Of course, extravasation could occur elsewhere in the pancreas but the relative deficiency of intra-islet immune cells implies that the cells do not gain entry via vessels located within the islets themselves. In this context, there is mounting evidence for the existence of a more generalized inflammatory process across the pancreas in Type 1 diabetes [28, 29] and it is possible that immune cells are recruited to islets from within the broader pancreatic parenchyma during insulitis. If so, then this raises a second issue; specifically, are immune cells recruited to the vicinity of the islets by an attractant signal? Most studies have assumed that islet inflammation arises from the secretion of powerful chemo-attractants from within the islet milieu and various potential chemokines have been mooted [30, 31] ; however, if this is the case, then it seems surprising that relatively few immune cells respond to these stimuli because the numbers reaching the islet periphery are small (typically, a few tens of cells per islet section, often fewer). This remains a conundrum, and one recent study has provided evidence that the expression of chemokines may be minimal in inflamed human islets [23] .
As illustrated in Fig. 1 , the influent immune cells are often arrayed around the peri-islet membrane. As such, inspection of images of inflamed human islets immediately suggest the existence of a physical barrier which impedes the further progress of immune cells towards the islet core. It is widely understood that islets are encased within a basement membrane composed of various proteoglycans, collagen and other fibrous proteins [32, 33] . As such, it seems likely that this structure will be porous to secreted hormones, chemokines and metabolites but impervious to immune cells. Thus, in order to mount a physical (rather than a purely 'chemical') attack on the b cells, the peri-islet barrier must be breached in order to allow the marauding immune cells direct access to their targets. As a means to understand this process more fully, we have recently modelled the immune attack using computational approaches and the outcomes have revealed that, somewhat surprisingly, among the myriad of factors which are likely to influence the rate of b-cell death, the formation of pores in the peri-islet basement membrane is of paramount importance [34] . Thus, future studies designed to understand how puncture of this barrier occurs during immune assault and whether adequate repair mechanisms can be activated in Type 1 diabetes are clearly warranted.
Insulitis: a heterogeneous process in Type 1 diabetes?
In addition to analysing the disposition of immune cells, a number of studies have also addressed the composition of the infiltrate in inflamed islets. Early investigations implied that CD8+ T cells are likely to play a major role in the process, and this has been confirmed in most subsequent work [21, 22, 24, 35] . These are generally assumed to represent CD8+ 'cytotoxic T cells', but this view has been brought into question by evidence implying that islet-associated CD8+ cells display features that are more reminiscent of tissue resident memory T cells [36, 37] . Thus, further characterization of the CD8+ cells present in inflamed islets is clearly required; not least, among people with Type 1 diabetes of different ages (see below).
Despite these lingering uncertainties, it was shown that the number of CD8+ cells increases in parallel with b-cell death in those islets where this process has already been initiated [21] . Moreover, although based on a cross-sectional analysis, it was proposed that a progressively increasing recruitment of CD8+ T cells correlates with enhanced b-cell killing. This would be consistent with the concept that these cells are the primary culprits mediating b-cell loss. This is also the case in the NOD mouse although, in these animals, the composition of the islet infiltrate may differ from that in humans because both CD8+ and CD4+ T cells are strongly represented [38, 39] . CD4+ cells are certainly present in insulitic infiltrates in humans, but they are fewer in number than CD8+ cells and the population size does not change significantly during the destructive phase of b-cell death [21, 22, 40] . Moreover, it remains to be established whether they are principally members of one specific CD4+ T-helper cell subclass.
In further support of the notion that CD8+ T cells are the primary mediators of b-cell death, careful analysis using 'tetramer' staining of pancreas sections has revealed that a proportion, at least, of the influent CD8+ T cells are reactive against specific b-cell peptide antigens [41] . Such cells are prime candidates to mediate b-cell cytotoxicity when they encounter the endocrine cells presenting their target peptides in the context of relevant cell surface major histocompatibility complex (MHC) class I molecules. In this regard, it is noteworthy that one of the defining characteristics of most b cells in people with recent-onset Type 1 diabetes is a dramatic upregulation ('hyper-expression') of MHC class I [42] . Thus, it is reasonable to conclude that antigen presentation to influent CD8+ T cells will be favoured in these circumstances.
Interestingly, CD8+ T cells are not alone in their capacity to respond to the signals promoting insulitis because, in some people, these are also accompanied by increasing numbers of cells expressing the surface marker CD20 [20] [21] [22] 35, 43] . Classically, CD20+ cells are defined as B lymphocytes and it is well established that B cells play a role in Type 1 diabetes [43] , not least because, when present in the circulation, they are responsible for secretion of antibodies, including the range of auto-antibodies commonly associated with progression to Type 1 diabetes. However, the fact that the islet-infiltrating B cells retain CD20 on their surface in humans (unlike the situation in NOD mice [44] ) implies that these are not primarily engaged in antibody secretion as this marker is normally downregulated when B cells differentiate into antibody secreting cells. In parallel, expression of the activation marker CD138 is increased but, in most of the Type 1 diabetes cases studied, those B cells present in the vicinity of inflamed islets do not express high levels of CD138 [21] . Thus, it seems a reasonable conclusion that the B cells present in inflamed islets are not there to secrete antibodies. Rather, they must play a separate role.
Clues as to what this function might be are few, but an important and unexpected advance has begun to shed light on the topic. This is because, while CD8+ T cells represent the majority population in essentially all Type 1 diabetes cases where this has been studied, the proportion of B cells is more variable [22, 35] . Importantly, this variation does not occur at the level of individual islets within a given pancreas but, rather, it is determined at the level of the person with Type 1 diabetes. Thus, some individuals display an islet infiltrate (in all inflamed islets) which is enriched in both CD8+ T and CD20+ B cells whereas, in others, the CD20+ B cells are present at much lower frequency. These features therefore define two distinct profiles of insulitis, which are each characterized by a preponderance of CD8+ T cells, but which differ in the relative (and absolute) numbers of B cells.
To denote this difference, we have termed these two profiles 'CD20Hi' and 'CD20Lo' [20, 22, 35] .
The precise origin and significance of these two insulitic profiles is still under investigation, but some important parameters have been established. Firstly, it was discovered that the two profiles diverge in parallel with the ages at which individuals are first diagnosed with Type 1 diabetes. Moreover, this divergence can be tracked over a relatively short window of time such that, among an initial group of 21 people studied (all of whom were diagnosed with Type 1 diabetes before the age of 20 years), those with the CD20Hi insulitic profile developed disease symptoms at~7 years of age while those with the CD20Lo profile were older (mean age of 13 years at diagnosis). Thus, even among a group of people who were selected because they had all been diagnosed with Type 1 diabetes before reaching the age of 20 years, two distinct sub-populations could be defined [22] .
Extension of this analysis to include a wider range of people with Type 1 diabetes showed that the pattern was maintained. Even more strikingly, it was clear that, among the cohort studied, any person diagnosed before the age of 7 years always displayed the CD20Hi profile of insulitis, whereas anyone diagnosed beyond the age of 13 years inevitably had the CD20Lo phenotype. This immediately suggests that, in humans, there are two uniquely distinct forms of insulitis which are differentially aggressive, such that the onset of symptoms occurs either at an earlier or a later age, respectively [22] .
Assuming that these deductions about the relative 'aggressiveness' of the two insulitic profiles are correct, then this could be taken to imply that the contribution of CD20+ B cells is a critical determinant of the overall outcome. In short, the presence of significant numbers of CD20+ cells as a component of the infiltrate appears to be associated with enhanced cytotoxicity and the early demise of the b cells. On this basis, it might be surmised that the role of the influent B cells is to regulate (positively) the cytotoxic potential of the CD8+ T cells. Alternatively, it is also conceivable that they may contribute to the killing process more directly, in their own right.
Clearly it will now be important to conduct further studies to reveal the role(s) played by the CD20+ cells during insulitis but, meanwhile, an important principle has emerged; not all insulitis is the same. This conclusion has important implications for the future design of immunotherapeutic trials targeting the cells mediating the autoimmune attack in Type 1 diabetes.
Insulitis: a variable outcome in Type 1 diabetes?
A further unexpected variable has been highlighted by the study of people with the two profiles of insulitis (CD20Hi and CD20Lo). This arose during experiments designed to map the proportions of insulin-containing islets present in fixed, paraffin-embedded, sections cut from the pancreases of those who died soon after receiving a diagnosis of Type 1 diabetes. The analysis revealed a surprising amount of variability but, importantly, this variability was not random.
There is a firm mantra that Type 1 diabetes arises wheñ 80% of the b cells present in an individual's pancreas have been destroyed [45] . Accordingly, one might imagine that variations in age at onset principally reflect differences in the time taken to achieve this extent of loss during the destructive process; however, recent evidence suggests that this is an over-simplification. In particular, it was found that people with Type 1 diabetes diagnosed beyond their early teenage years retain a much higher proportion of insulin-containing islets at diagnosis than those diagnosed before the age of 7 years [22] . Thus, younger individuals (with a CD20Hi profile of insulitis) fulfil the expectation that disease symptoms arise when most b cells are lost. By contrast, among those diagnosed at older ages (the CD20Lo group) this is less certain. Rather, these individuals can apparently develop diabetes while still retaining a significant b-cell reserve. So, in one sense, this evidence supports the view that the two forms of the insulitis are differentially aggressive because one (CD20Hi) leads to a much earlier and more extensive b-cell loss than the other. However, a second factor also comes into play because those with the CD20Lo phenotype seem to develop Type 1 diabetes when they still have more b cells in their pancreas than might be expected. Therefore, among these people, it seems possible that not only b-cell loss but also a functional insulin secretory deficit contributes to disease onset. Whether and how this secretory dysfunction might be related to the immune cell profiles is unclear, but this is certainly worthy of further study.
Interestingly, these histological data are borne out by analysis of C-peptide levels in patients at diagnosis. C-peptide concentrations were lowest in patients from the youngest age groups at disease onset while those diagnosed at older ages retained significantly more C-peptide [46] . This again implies that older people with Type 1 diabetes (who presumably display a CD20Lo insulitic profile) retain a greater number of b cells at diagnosis and thereby develop the disease in the face of higher pancreatic insulin levels than those who are younger. This provokes the unexpected conclusion that the timing of the onset of Type 1 diabetes may not be determined solely by the rate at which b cells are killed but also by their relative functionality.
Insulitis: an inevitable conclusion in Type 1 diabetes?
The insight that residual b-cell numbers may vary in different people at the onset of Type 1 diabetes according to age (which can be taken as a surrogate for the profile of insulitis) begs a second question in relation to the final outcome of the disease process. Once again, the popular view conceives the process of insulitis as having a final and inevitable consequence: that few, if any, b cells will be present in the pancreas within a few years of the initial diagnosis of disease, even among those with the highest starting values and slower rates of decline. Emerging evidence, however, implies that this view is also over-simplified.
A primary challenge to the idea has come from the histological analysis of pancreas sections taken from people who have lived with Type 1 diabetes for >50 years. In several cases, it has been possible to examine the pancreases of members of this group post mortem, and a big surprise has emerged. Contrary to all expectation, some of these contain persisting b cells, not simply as individual cells or small groups of cells within the pancreas (although both exist) but also in the form of islets having a very typical morphology and clear insulin immunopositive cells [47] . An example is shown in Fig. 2 from an individual who had lived with Type 1 diabetes for >50 years by the time of their death. It is important to emphasize that not all islets survive in this form because the vast majority are devoid of b cells. Among the larger sea of insulin-deficient islets, however, a few retain (or perhaps, have regained?) a near-normal b-cell complement. This then raises the inevitable question: why and how do these b cells persist? This is a question to which there are currently no specific answers but, interestingly, there are a few hints.
Firstly, an obvious possibility is that some b cells may be persuaded to undergo mitosis during the autoimmune attack such that the persistence of b cells then reflects a process of ongoing cell division in which new b cells are constantly regenerated. This idea runs counter to the widely held concept that human b cells do not undergo mitosis to any significant extent beyond the very earliest years of life [48, 49] . Nevertheless, extensive b-cell proliferation has been reported in the pancreas of an elderly person with Type 1 diabetes [40] and we have found a 10-fold rise in the number of islets with mitotic b cells in a group of people newly diagnosed with Type 1 diabetes, when compared to agematched people without diabetes [50, 51] . This evidence implies that the favoured dogma should be revised to accept that b cells can, and do, divide in people with Type 1 diabetes. Whether this accounts for their long-term persistence in older people with Type 1 diabetes, however, remains to be established.
A second important possibility is that, by some (undefined) means, certain cells can survive the immune assault and effectively 'lie low' in the pancreas until the autoimmune attack subsides. This hypothesis, of course, implies that the attack does subside over time and there is only limited evidence to support this in humans, although it is known that auto-antibody levels decline over time after disease onset [52] . Very recently, it has been revealed in the NOD mouse, that some b cells are unusually resistant to autoimmune-mediated destruction and can survive the initial immune onslaught [53] . Perhaps the finding of b cells in people with long-term disease implies that an equivalent mechanism might also be operative in humans? In support of this, it is increasingly accepted that human b cells are heterogeneous [54] and it is plausible that a sub-population might exist which is relatively resistant to autoimmune attack, at least in some individuals. If so, then it is important to gain a more complete understanding of the factors influencing this susceptibility and, encouragingly, evidence is already beginning to emerge.
In particular, it has been noted that the classic hyperexpression of MHC class I, which characterizes the b cells of people with recent-onset Type 1 diabetes, is not found universally among all islets. Certainly it is our experience that the vast majority of insulin-containing islets display this phenomenon in people with recent-onset Type 1 diabetes but occasional insulin-containing islets have also been found which do not display the response (Fig. 3 ). These are rare but, where they occur, they can lie immediately adjacent to others which hyper-expresss MHC class I, suggesting that there is some intrinsic mechanism which precludes certain islets from responding. If, then, it is the case that elevated MHC class I represents a primary signal by which immune influent immune cells recognize and target b cells, it follows that any b cells that manage to avoid the MHC class I hyperexpression, may be relatively protected. In support of this, we have also found that, over time, the proportion of residual insulin-containing islets with ongoing MHC class I hyper-expression declines [42] . Thus, people who have lived with Type 1 diabetes for about a decade before their pancreas becomes available for study, have a reduced proportion of residual insulin-containing islets with evident MHC class I hyper-expression. This could reflect the fact that these cells have never hyper-expressed MHC class I or, alternatively, it could be that they have downregulated this response over time. Either way, perhaps the key lies in elevated MHC class I expression and that, for unknown reasons, some b cells either fail to respond, or do not sustain their response to, the ambient triggers that otherwise promote MHC class I upregulation. As a result, they remain 'hidden' from the invading immune cells.
Of course, the surprising discovery that b cells can persist long after the onset of Type 1 diabetes offers hope that intervention strategies might be devised in future by which such cells could be 're-invigorated'. This then raises the exciting possibility that people with Type 1 diabetes might be stimulated to recover at least some functional insulin secretion capacity which would, in turn, improve their quality of life and may delay the onset of complications.
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